Paper Details

  1. Home
  2. Paper Details

Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial.

Author: BarèM, CalvetX, CubellsM, GálvezE, López-LorenteM, MolinaE

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

One-week triple therapy (omeprazole, clarithromycin, and amoxycillin) was superior to two-week dual therapy (omeprazole and clarithromycin) for Helicobacter pylori eradication in patients with duodenal ulcer. However, the cure rate in primary care was far below 90%.
Paper Details　
Original Abstract of the Article :
BACKGROUND: One-week triple therapy has been suggested to be superior to two-week omeprazole-clarithromycin therapy for the cure of Helicobacter pylori infection. However, direct comparisons of the two treatments are scarce. AIM: To compare triple with dual therapy for H. pylori infection in the pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.1999.00552.x

データ提供：米国国立医学図書館（NLM）

Helicobacter pylori: A Persistent Desert Dweller

Helicobacter pylori is a tenacious bacterium that can colonize the stomach, leading to various gastrointestinal problems. This research explores the efficacy of different treatment regimens for eradicating H. pylori infection, comparing two-week dual therapy with one-week triple therapy. It's like battling a persistent desert dweller, seeking the most effective strategy to eliminate the threat.

Finding the Right Oasis: Triple Therapy Shows Superiority

The study found that one-week triple therapy was superior to two-week dual therapy in eradicating H. pylori infection. This is like discovering a more effective oasis, providing a greater chance of success in the fight against the desert dweller. The authors observed a significantly higher eradication rate in the triple therapy group, suggesting that a more aggressive approach might be necessary to effectively eliminate this resilient bacteria.

Navigating the Desert of Infections: Understanding Treatment Strategies

This research emphasizes the importance of choosing the right treatment strategy for H. pylori infection. It's like selecting the best path through a desert, ensuring a successful journey to conquer the challenge. By understanding the effectiveness of different therapies, we can make informed decisions to optimize treatment outcomes and improve patient well-being.

Dr.Camel's Conclusion

This research underscores the importance of selecting the most effective treatment regimen for H. pylori infection. It's like choosing the right tools for a desert expedition, ensuring a successful journey. One-week triple therapy appears to be a promising option, offering a higher chance of eradication and reducing the duration of treatment.

Date :
  1. Date Completed 1999-07-20
  2. Date Revised 2019-08-31
Further Info :

Pubmed ID

10383508

DOI: Digital Object Identifier

10.1046/j.1365-2036.1999.00552.x

Related Literature

Article Analysis
・Side Effects of omeprazole clarithromycin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.